April 28 is ESOT – European Society for Organ Transplantation Action Day, a day where it calls for enhanced cooperation between EU member states to address inequalities in transplantation

April 28 is ESOT – European Society for Organ Transplantation Action Day. ESOT is calling for enhanced cooperation among EU member states to empower transplant centres in delivering consistent, high-quality transplantation service ahead of the EU elections. ESOT is looking to drive the following 5 actions in the European Parliament between 2024 and 2029: Read […]

April 28 is ESOT – European Society for Organ Transplantation Action Day, a day where it calls for enhanced cooperation between EU member states to address inequalities in transplantation Read Post »

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients

Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients Read Post »

“Outnumber PAH” a new campaign launched by Merck to spread awareness and empower people with pulmonary arterial hypertension

“Outnumber PAH” is a new campaign launched by Merck to spread awareness and empower pulmonary arterial hypertension patients. The website features medical information about pulmonary hypertension and sections on living with the condition, patient stories and a conversation guide. Find out more at this link

“Outnumber PAH” a new campaign launched by Merck to spread awareness and empower people with pulmonary arterial hypertension Read Post »

The Fundación Contra la Hipertensión Pulmonar, Spain, has won an important prize for its project on non-invasive remote monitoring for children with pulmonary hypertension

The Spanish Foundation for Pulmonary Hypertension, Fundación Contra la Hipertensión Pulmonar, has been selected as winner of one of the prizes of the “Inocente Foundation” for its project on “Non-invasive Remote Monitoring for children with Pulmonary Hypertension”, which will be carried out at the Ramón y Cajal University Hospital.

The Fundación Contra la Hipertensión Pulmonar, Spain, has won an important prize for its project on non-invasive remote monitoring for children with pulmonary hypertension Read Post »

Findings from the UK Pulmonary Hypertension Association’s survey on nutrition and pulmonary arterial hypertension now available

The UK Pulmonary Hypertension Association launched a survey on nutrition and pulmonary arterial hypertension last year in March in which they asked patients about eating habits, food preferences, and cooking or weight management challenges. The findings were announced at the Pulmonary Vascular Research Institute (PVRI)’s congress in January 2024 and, more recently, on social media.

Findings from the UK Pulmonary Hypertension Association’s survey on nutrition and pulmonary arterial hypertension now available Read Post »

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Read Post »

Mutations in the TBX4 gene are associated with the development of pulmonary arterial hypertension in children. Anton Morkin, the father of a young patient, has created a TBX4 global community

Mutations in the TBX4 gene can cause not only heritable pulmonary arterial hypertension (HPAH) in children but also skeletal anomalies causing issues with the knee and hip joints. TBX4 mutations can cause another serious illness, Interstitial Lung Disease in Childhood (chILD), which is also incurable. Anton Morkin is the father of a young boy who

Mutations in the TBX4 gene are associated with the development of pulmonary arterial hypertension in children. Anton Morkin, the father of a young patient, has created a TBX4 global community Read Post »

Navigating sex and intimacy while living with pulmonary hypertension, a live webinar organised by the Pulmonary Hypertension Association of Canada (PHA Canada), April 29, 20:00 CET

Drs. Vargas and Ventetuolo will discuss sexual health and intimacy for individuals living with pulmonary hypertension and their partners in this PHA Canada live webinar on April 29, 2024. They will explore prior research, clinical observations, and insights gathered from their own interviews and surveys with pulmonary hypertension patients. This webinar aims to shed light

Navigating sex and intimacy while living with pulmonary hypertension, a live webinar organised by the Pulmonary Hypertension Association of Canada (PHA Canada), April 29, 20:00 CET Read Post »

April 7 is World Health Day 2024, celebrated annually by the World Health Organisation (WHO). This year’s theme is “My health, my right”

April 7 is the UN “World Health Day”. This date marks the anniversary of the founding of World Health Organization in 1948. Health is a human right: everyone, everywhere, should have access to quality health services. This year’s theme was chosen to champion the right of everyone, everywhere to have access to quality health services, education, and

April 7 is World Health Day 2024, celebrated annually by the World Health Organisation (WHO). This year’s theme is “My health, my right” Read Post »

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages

The full transcripts of the Alliance for Pulmonary Hypertension’s 2023 six webinars are now available! The transcripts encapsulate invaluable insights that continue to resonate with current trends and emerging issues, serving as a vital resource for our community. They are now in a format that can be translated into 40 languages, thanks to the embedded

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages Read Post »

The remarkable journey of two individuals with hand transplants, Theo Kelz and Vasyly Rohovyy

Two exceptional people feature in this photo: on the left Mr. Theo Kelz, the first patient to have a hand transplant in Austria in the year 2000, and on the right Mr Vasyly Rohovyy, who had both hands transplanted in Vienna in 2006.  The photo was taken under the portrait of Professor Raimond Margraiter, the

The remarkable journey of two individuals with hand transplants, Theo Kelz and Vasyly Rohovyy Read Post »

Surgical interventions in chronic thromboembolic pulmonary hypertension (CTEPH) live Alliance for Pulmonary Hypertension webinar, April 29, 2024

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension characterized by the presence of organized thromboembolic material (clots) and vascular remodeling. It is classified in group 4 of the current official World Health Organization classification of pulmonary hypertension. The 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines on pulmonary hypertension advocate a

Surgical interventions in chronic thromboembolic pulmonary hypertension (CTEPH) live Alliance for Pulmonary Hypertension webinar, April 29, 2024 Read Post »

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024

Dr. Joanna Pepke-Zaba, renowned consultant respiratory physician at Royal Papworth Hospital, recently received a prestigious European Respiratory Society (ERS) lifetime achievement award, marking another milestone in her illustrious career. In an interview with Saša Janković, recently published on March 18, 2024 on “Hospital Health Care Europe”, Dr. Pepke-Zaba discusses her dedication to advancing research and

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024 Read Post »

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024

The Annual General Assembly of the French Pulmonary Hypertension Association HTaPFrance is taking place in Paris on Saturday the 6th of April 2024 in Paris. The morning program is dedicated to the presentation of the annual report of activities, vote on financial report and approval of new members of the Board. The afternoon program features

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024 Read Post »

“Patient Involvement in Guidelines”, a webinar organised by ERKNet and EURORDIS, featuring Matt Bolz-Johnson as speaker, April 22, 2024

Clinical practice guidelines provide essential recommendations for diagnosing and treating medical conditions. In the realm of pulmonary hypertension a groundbreaking milestone has been achieved with the inclusion of two patient representatives, Pisana Ferrari and Gergely Meszaros JD, MSc, as members of the dedicated task force and co-authors of the new guidelines jointly developed by the European Society of Cardiology and the European Respiratory

“Patient Involvement in Guidelines”, a webinar organised by ERKNet and EURORDIS, featuring Matt Bolz-Johnson as speaker, April 22, 2024 Read Post »

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024

The US Food and Drug Administration has approved sotatercept, Merck‘s new drug for pulmonary arterial hypertension. It’s commercial name is Winrevair. Read more on the FDA website at this link Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It was evaluated as an add-on to stable background therapy for the treatment of pulmonary

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024 Read Post »

Full transcript of webinar n° 5 – 2023

“ADVANCING CTEPH CARE: EXPLORING THE MULTIMODAL STRATEGY IN THE NEW ESC/ERS GUIDELINES”, November 21, 2024 NB. This transcript can be translated into your preferred language – use orange button at the bottom centre of this page to select it (slides are not translatable). DR. ANDREAS REIMANN, MODERATOR Today, we’ll delve into chronic thromboembolic pulmonary hypertension,

Full transcript of webinar n° 5 – 2023 Read Post »

Full transcript of webinar n° 4 – 2023

“INTRODUCING THE INNOVATIONS IN THE 2022 PULMONARY HYPERTENSION TREATMENT ALGORITHM“, October 12, 2023 NB. This transcript can be translated into your preferred language – use orange button at the bottom centre of this page to select it (slides are not translatable). ROBERT PLETICHA, MODERATOR Hello, welcome everyone. Today’s live event is titled: “Introducing the innovations

Full transcript of webinar n° 4 – 2023 Read Post »

TRANSLATE »
Scroll to Top